MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

Search

Fate Therapeutics Inc

Abierto

SectorSanidad

1.3 -2.99

Resumen

Variación precio

24h

Actual

Mínimo

1.26

Máximo

1.36

Métricas clave

By Trading Economics

Ingresos

-4.5M

-52M

Ventas

-1.2M

1.9M

BPA

-0.44

Margen de beneficios

-2,803.925

Empleados

181

EBITDA

10M

-42M

Recomendaciones

By TipRanks

Recomendaciones

Comprar

Estimación a 12 Meses

+357.04% upside

Dividendos

By Dow Jones

Próximas Ganancias

8 may 2025

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

26M

143M

Apertura anterior

4.29

Cierre anterior

1.3

Puntuación técnica

By Trading Central

Confianza

Weak Bullish Evidence

Fate Therapeutics Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

24 abr 2025, 23:54 UTC

Acciones populares

Stocks to Watch: Alphabet, Intel, AppFolio

24 abr 2025, 23:51 UTC

Charlas de Mercado

Gold Edges Higher, Supported by U.S. Dollar Weakness -- Market Talk

24 abr 2025, 23:46 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

24 abr 2025, 23:46 UTC

Charlas de Mercado

Nikkei May Rise on Hopes for Easing U.S.-China Trade Tensions -- Market Talk

24 abr 2025, 23:37 UTC

Principales Noticias

Big Tech Braces for Tariff-Induced Advertising Slowdown -- WSJ

24 abr 2025, 23:36 UTC

Principales Noticias

Tokyo Consumer Inflation Accelerates in April as Companies Raise Prices

24 abr 2025, 23:13 UTC

Principales Noticias
Ganancias

Google's Earnings Power Holds Up in Global Turbulence -- Update

24 abr 2025, 23:09 UTC

Principales Noticias

Trump Initiatives Knocked Back in a New Round of Court Rulings -- 2nd Update

24 abr 2025, 23:02 UTC

Adquisiciones, fusiones, absorciones

SK Telecom to Sell 10.8M Kakao Shares via After-Hours Block Trading

24 abr 2025, 23:02 UTC

Adquisiciones, fusiones, absorciones

SK Telecom to Dispose of 2.4% Stake in Kakao to Raise KRW413.27B

24 abr 2025, 22:51 UTC

Principales Noticias
Adquisiciones, fusiones, absorciones

Germany's Merck Nears Roughly $3.5 Billion Deal for SpringWorks -- Update

24 abr 2025, 22:48 UTC

Principales Noticias

Walmart Walks the DEI Tightrope in Latest Proxy Statement -- Barrons.com

24 abr 2025, 22:47 UTC

Charlas de Mercado

Intel Remains in Tough Position, CFRA Research Analyst Says -- Market Talk

24 abr 2025, 22:38 UTC

Charlas de Mercado
Ganancias

Tariffs Hurt Intel's 2Q Outlook as CFO Warns Economic Slowdown is Likely -- Market Talk

24 abr 2025, 22:24 UTC

Ganancias

Aluminum Corp. of China: Increase in Product Sales Supported 1Q Results >2600.HK

24 abr 2025, 22:24 UTC

Ganancias

Aluminum Corp. of China 1Q Rev CNY55.78B Vs. CNY48.96B >2600.HK

24 abr 2025, 22:24 UTC

Charlas de Mercado
Ganancias

Intel's Comeback Involves More Engineers, More In-Office Work -- Market Talk

24 abr 2025, 22:23 UTC

Ganancias

Aluminum Corp. of China 1Q Net CNY3.54B Vs. Net CNY2.23B >2600.HK

24 abr 2025, 22:11 UTC

Charlas de Mercado
Ganancias

Global Equities Roundup: Market Talk

24 abr 2025, 22:11 UTC

Charlas de Mercado
Ganancias

Intel CEO: Layoffs Will Simplify Company Structure -- Market Talk

24 abr 2025, 22:09 UTC

Principales Noticias
Ganancias

Intel Cuts Outlook, Says Layoffs Are in Store -- Update

24 abr 2025, 22:00 UTC

Charlas de Mercado
Ganancias

T-Mobile's Key Subscriber Metric Disappoints Despite Earnings Beat -- Market Talk

24 abr 2025, 21:39 UTC

Principales Noticias

Trump Initiatives Knocked Back in a New Round of Court Rulings -- WSJ

24 abr 2025, 21:24 UTC

Principales Noticias
Ganancias

Bristol Myers Reports Better-Than-Expected Earnings. The Future Is Cloudy. -- Barrons.com

24 abr 2025, 21:24 UTC

Principales Noticias
Ganancias

Google's Earnings Power Holds Up in Global Turbulence -- WSJ

24 abr 2025, 21:23 UTC

Principales Noticias
Ganancias

Intel Cuts Outlook, Says Layoffs Are in Store -- WSJ

24 abr 2025, 21:04 UTC

Ganancias

T-Mobile Reports Strong Earnings but Its Wireless Results Disappoint. The Stock Is Sliding. -- Barrons.com

24 abr 2025, 21:03 UTC

Ganancias

Agnico-Eagle Mines Believes Its Rev Structure Will Be Largely Unaffected by the Tariffs >AEM.T

24 abr 2025, 21:03 UTC

Ganancias

Agnico-Eagle Mines Total Expected Capex for 2025 Still Estimated at $1.75 B to $1.95 B >AEM.T

24 abr 2025, 21:02 UTC

Ganancias

Agnico-Eagle Mines Positioned to Achieve 2025 AISC Per Ounce Guidance of $1,250 to $1,300. >AEM.T

Comparación entre iguales

Cambio de precio

Fate Therapeutics Inc previsión

Precio Objetivo

By TipRanks

357.04% repunte

Estimación a 12 Meses

Media 6.17 USD  357.04%

Máximo 12 USD

Mínimo 2.5 USD

De acuerdo con 12 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Fate Therapeutics Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

12 ratings

4

Comprar

8

Mantener

0

Vender

Puntuación técnica

By Trading Central

0.8624 / 1.49Soporte y Resistencia

Corto Plazo

Weak Bullish Evidence

Medio plazo

Strong Bullish Evidence

Largo Plazo

No Evidence

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Fate Therapeutics Inc

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.